Platelet glycoprotein VI (GPVI)–targeted antithrombotic strategies in acute ischaemic stroke, w[...]

Organisation / Company Institut national de la santé et de la recherche médicale (INSERM) Laboratory UMR_S 1255_ Biologie et pharmacologie des plaquettes sanguines Is the Hosting related to staff position within a Research Infrastructure? Yes

Keywords: Platelets, Glycoprotein VI (GPVI), Acute ischaemic stroke, Thrombo inflammation, Platelet–leukocyte interactions

A major focus of the research team is on evaluation of the importance of platelet glycoprotein VI (GPVI) as a safe, innovative antithrombotic target to improve outcome after acute ischaemic stroke, with a focus on thrombo inflammation during reperfusion. Work spans experimental stroke models, advanced histology, flow cytometry and microfluidics to dissect platelet–leukocyte–endothelium interactions in the ischaemic brain.

Current projects investigate how human GPVI aggravates cerebral lesions by driving neutrophil and monocyte recruitment, edema and microvascular dysfunction, and how pharmacological GPVI inhibition with glenzocimab reduces ischemic damage without increasing bleeding. Clinical translation builds on ACTIMIS/ACTISAVE trials to characterise safety, haemorrhagic risk and functional outcomes when GPVI inhibition is added to thrombolysis and thrombectomy.

A postdoctoral project could focus on mapping GPVI dependent thrombo inflammatory pathways (e.g. platelet–neutrophil aggregates, NETs, endothelial activation) and identifying biomarkers or imaging and blood signatures predicting which fully recanalised patients benefit most from GPVI inhibition.

Who can apply?

Researchers of any nationality who:

• Have completed a PhD or will complete it at the date of the call deadline (September 2026).
• Have a maximum of 8 years full-time equivalent experience in research at the time of the call deadline.
• Have not resided or carried out their main activity (work, studies, etc.) in France for more than 12 months in the 3 years immediately prior to the call deadline.

Beware that applicants who have applied to the MSCA Postdoctoral Fellowship 2025 call and received an evaluation below 80% are not eligible for an application in 2026.

How to apply?

We encourage all motivated and eligible postdoctoral researchers to send their expressions of interest to the supervisor’s e‑mail address before 24th April 2026.

Your application shall include:

• a CV (5 pages max)
• a cover letter outlining your research background and its synergies with the supervisor’s field and/or the proposed research topic.

Estimated timetable:

• Deadline for sending an expression of interest: 24th April 2026
• Selection of the applicant: May 2026 at the latest